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Abstract We have recently reported the cloning of a cDNA 
coding for a stress inducible human chaperonin 10. The protein 
was shown to possess 100% identity with the bovine homologue 
and a single amino acid replacement (glycine to serine at position 
52) compared to rat chaperonin 10. Here we report the heteroio- 
gous expression of human chaperonin 10 in Escherichia coil, its 
purification and its functional characterization. The recombinant 
protein was purified to homogeneity as judged by different analyt- 
ical techniques, and mass spectrometry analysis showed a MW 
of 10,801 Da in agreement with the predicted sequence. This 
molecular weight accounts for a protein which is not modified 
post-translationally. In fact, natural rat chaperonin 10 has been 
shown to be acetylated at the N-terminus, a feature suggested to 
be important for targeting and functional activity. Here we show 
that recombinant human chaperonin 10 is fully active in assisting 
the chaperonin 60 GroEL in the refolding of denatured yeast 
enolase, thereby showing that, at least in the present system, 
post-translational cetylation is not necessary for its activity. 
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Recently, we have identified and cloned a cDNA encoding 
the human cpnl0 [10]. It showed a 100% homology with the 
bovine cpnl0 [11] and possessed a single amino acid substitu- 
tion, serine in place of glycine at position 52, compared to rat 
cpnl0 [12]. A recent report has shown that human cpnl0 is 
identical to the early pregnancy factor (EPF) [13]. EPF has been 
known for long time to be involved in a number of physiolog- 
ical processes which are apparently unrelated to the role of 
cpnl0 in protein folding, but its characterisation has been elu- 
sive due to the difficulties encountered in its purification [13]. 
Here, we report the high-level expression of human cpnl0 in 
Escherichia coli. A single-step urification procedure nabled 
us to purify the protein to homogeneity and to characterise it 
by mass spectroscopy and N-terminal sequencing. The recom- 
binant human cpn 10, which is not acetylated atthe N-terminus 
residue, was fully functional in refolding experiments in vitro 
ere we employed GroEL as cpn60 and denatured yeast enolase 
as target protein. 
2. Materials and methods 
1. Introduction 
Molecular chaperons are proteins which facilitate correct 
i olding and assembly of nascent polypeptide chains in bacteria, 
I ungi, plants and animals [1,2] Members of this class of proteins 
,~re the Escherichia coli heat shock proteins GroEL (heat shock 
!~rotein 60, HSP60) and GroES (HSP10), which have been 
ermed also chaperonins 60 and 10. The GroEL/GroES com- 
~lex, which assists protein folding in a catalytic process requir- 
ing K ÷ and Mg-ATP [3], is the most studied chaperonin (cpn) 
-,ystem. In its native form, GroEL forms a double stacked ring, 
~:ach ring comprising seven ---60 kDa subunits, while GroES is 
nade up of a single ring of seven = 10 kDa subunits. Both share 
a high degree of homology with prokaryotic and eukaryotic 
~quivalents, suggesting a general mechanism inpromoting pro- 
ein folding [4]. 
Thus, GroES homologues have been identified in many 
:grokaryotes, plant chloroplasts and yeast, plant and mammal- 
an mitochondria [5-9]. 
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2.1. Materials 
Guanidine hydrochloride (GdnHC1) was purchased from Fluka. 
Enolase, 2-phosphoglyceric a id, nucleotides were obtained from 
Sigma. GroES and GroEL and restriction enzymes were obtained from 
Boehringer. All other reagents, at the highest degree of purity, were 
purchased from Merck and Fluka. 
2.2. Cloning of human chaperonin 10 into E. coli expression vector 
pET-11d 
The total RNA extracted from heat shocked human hepatoma cell 
line HepG2 was amplified by reverse transcription-polimerase chain 
reaction (RT-PCR) using 2 l mer 5' and 18mer 3' oligonucleotides of rat 
cpnl0 cDNA as primers [12]. 
In addition the primers included aNcol and a BamHI sites uitable 
for cloning the PCR product into pET-I ld [14]. The complete se- 
quences of the primers are 5"-GCGCGCGGATCCATGGCTGGA- 
CAAGCTTTTAGG-3' and 5'-GCGCGCAAGCTTGG ATCCTCA- 
GTCGACATACTTTCC-3' for the human cpnl0 5' and 3' ends, re- 
spectively. The 5' end primer ?;col restriction site provided an ATG 
codon just upstream the GCA triplet hat codes for the first residue of 
the native protein, an alanine. The T7 expression vector was obtained 
by cloning the NcoI and BamHI restriction fragment from the human 
cpnl0 cDNA into pET-1 ld after digestion with NcoI and BamHI. The 
resulting plasmid coding for human cpnl0 was named pET-hucpnl0. 
The sequence analysis of the amplified product cloned into the expres- 
sion vector was carried out with the Sequenase kitversion 2.0 (United 
States Biochemical Co., Cleveland, OH, USA). 
The accession number of human chaperonin 10 is EMBL Ac. No. 
X75821. 
Human cpnl0 gene corresponds toHSPE1 according to the Guidelines 
l'or Human Gene Terminology [Shows et al. (1987) Cytogenet. Cell 
Genet. 44, 11]. 
2.3. Expression of human cpnlO in E. coli 
Plasmid pET-hucpnl0 was transformed into BL21(DE3) pLysS. For 
expression, cells were grown at 37°C in ZBM9 medium supplemented 
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with 50/.tg/ml of ampicillin and 34 pg/ml of chloramphenicol to an 
OD60 o of 0.6-1. Isopropyl fl-D-thiogalactopyranoside was added to 0.4 
mM, and cells were shaken for additional 3h. The cells were harvested 
by centrifugation, resuspended in lysis buffer, 50 mM Tris-HC1, 2 mM 
EDTA, pH 8, at a concentration of 20 OD60o/ml and stored at -20°C 
until used. 
2.4. Purification of recombinant human cpnlO 
Frozen cells were thawed at 4°C and sonicated over ice at an ampli- 
tude of 18/~m for 1 min intervals with 1 rain cooling for a total of 10 
min. Cell sonicate was spun in a Sorvall (DuPont) GSA rotor at 5000 
rpm for 10 min at 4°C to remove debris and intact cells. The superna- 
tant was centrifuged at 55,000 × g in a TST 2817 rotor with a Kontron 
Centrikon T-1065 for 1 h at 4°C. The resulting pellet was resuspended 
in 5 M urea, 0.045% trifluoroacetic a id (TFA), centrifuged in a Sorvall 
GSA rotor at 4000 rpm for 10 min at 4°C and then dialysed against 
2% acetonitrile, 0.1% TFA (buffer A) overnight. The sample was centri- 
fuged again as before and filtered through an 0.45/lm filter before 
chromatographic purification. The human cpnl0 was then applied to 
a Vydac C18 reverse phase HPLC (RP-HPLC) column (10 × 300 mm) 
equilibrated in buffer A described above. Elution was carried out with 
a three-step gradient of acetonitrile containing 0.8% TFA: (1) from 0 
to 32% in 91 min; (2) from 32 to 50% in 90 rain; and (3) from 50 to 80% 
in 30 min, at flow rate of 2.5 ml/min. Column effluent was monitored 
at A22o nm. The purified recombinant product was analysed by RP- 
HPLC using an analytical Vydac C18 (4.6 × 150 mm) column using a 
linear gradient of buffer B from 0 to 55% of buffer B in 55 rain. 
2.5. Binding of recombinant human cpnlO to GroEL 
Gel filtration experiments were performed using a Superose 6 FPLC 
column (Pharmacia) and the following eluent: 100 mM Tris-HCl, 10 
mM KC1, 7 mM MgSO4, pH 7.8 containing 0.25 mM ATP. Prior to 
injection, samples of GroEL and either GroES or human chaperonin 
10 were prepared in the above buffer supplemented with 0.6 mM ATP. 
Controls were made without addition of ATP. After 15 min incubation 
at room temperature samples were applied onto the column and peaks 
corresponding toGroEL and GroEL-cpn complex were collected man- 
ually and lyophilised. Lyophilized material was resuspended in 200 ,ul 
of water and proteins were precipitated by the addition of 800/A of cold 
acetone. After centrifugation precipitates were dissolved in SDS-buffer 
and analyzed by SDS-PAGE. 
2.6. Refolding assays 
Yeast enolase refolding assay was performed as previously described 
[15]. Briefly, yeast enolase (Sigma, 80 units/mg) was denatured in 4 M 
GdnHC1 at room temperature for at least 4 h and then diluted 60 fold 
into refolding buffer (50 mM Tris-HC1, pH 7.8, containing 10 mM 
Mg(CH3COO)2, 20 mM KCI, and 2 mM dithiothreitol, either with or 
without ADP 4 mM). GroEL, GroES and human ehaperonin 10 where 
added to the refolding buffer where stated. Refolding reaction were 
carried out at 25°C. 
The refolding mixture was diluted 25-fold into the assay buffer (50 
mM Tris-HCl, pH 7.8, containing 1mM 2-phosphoglyeeric acid and 
1 mM MgCI2), and enolase activity was assayed at 240 nm monitoring 
the formation of phosphoenolpyruvate. 
2. 7. Additional analytical techniques 
BCA protein assay reagent (Pierce) was utilised to determine protein 
content [16]. Sodium dodecyl sulfate-polyacrilamide gel lectrophoresis 
(SDS-PAGE) was performed with a 8-25 polyacrylamide gradient gel 
using a Phast System instrument (Pharmacia) ccording to the Laemmli 
method [17]. Protein sequencing was performed by automated Edman 
degradation using an Applied Biosystem 475A instrument. Electron 
Spray Ionization-Mass Spectrometry (ESI-MS) was performed on a 
Finnigan MAT model 700 instrument. 
3. Results 
RT-PCR amplification of total RNA from human hepatoma 
cell line HepG2, using the primers described in section 2, 
yielded a cDNA product of =300 bp (data not shown). The 
DNA was digested sequentially with NcoI and BamHI and 
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Fig. 1. RP-HPLC analysis of recombinant human cpnl0 using a Vydac 
C18 column to assess purity of the protein (see section 2 for details). 
cloned directly into pET-1 ld plasmid Ncol and BamHI restric- 
tion sites in order to generate xpression plasmid pET-hucpnl0. 
The recombinant plasmid was then inserted into E. coli strain 
BL21(DE3) pLysS for expression. 
SDS-PAGE analysis of induced total cell lysate indicated the 
presence of a band of =10 kDa present in the recombinant 
strain, but absent in a non-recombinant one (data not shown). 
Most of the recombinant protein was found in the pellet ob- 
tained after ultra centrifugation i dicating that the product was 
insoluble. Therefore, the pellet was resuspended in 5 M urea 
containing 0.045% TFA. The resuspended pellet from 1 litre 
culture was dialysed overnight against 2% acetonitrile, 0.1% 
TFA and then applied onto a semi-preparative C18 Vydac 
RP-HPLC column where the recombinant human cpnl0 was 
recovered as a single peak. Fig. 1 shows an analytical RP- 
HPLC run with an aliquot of purified material, indicating a 
purity of the recombinant protein of >95%. Moreover, this 
preparation is not contaminated with detectable levels of 
GroES which shows a different mobility both in SDS-PAGE 
and RP-HPLC (data not shown). The estimated yields were 
about 10 mg of purified protein per litre of culture. Although 
the recombinant human cpnl 0 was originally found to be insol- 
uble, after purification the lyophilised protein showed to be 
fully soluble in water. ESI-MS of the recombinant human 
cpnl0 showed a molecular weight of the recombinant protein 
of 10801 Da as predicted from its deduced amino acid sequence 
lacking starting methionine (Fig. 2). N-terminal sequencing of 
the first 10 residues of the purified protein confirmed the ex- 
pected sequence for the human cpn 10 [1 O] indicating again that 
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t ig. 2. ESI-MS of recombinant human cpnl0, displayed as multiply 
1 rotonated molecular ions. The inset shows computer reconstruction 
(f the molecular mass. 
the initial methionine introduced uring the amplification of 
~e  cDNA was removed by E. coli [18]. 
The recombinant human cpnl0 was then tested for its ability 
1o bind the E. coli cpn60 GroEL. Fig. 3 shows a silver-stained 
YiDS-PAGE analysis of peaks obtained after gel filtration ex- 
?eriments. Upon addition of ATP to the incubation buffer the 
i~resence of a band corresponding to human cpnl0 was detect- 
;~ble analysing the GroEL peak. The band was undetectable 
, ,mitting the nucleotide in the incubation buffer. We then tested 
ecombinant human cpnl0 in the refolding assay of yeast eno- 
',ase. When yeast enolase is denatured with GdnHC1, its subse- 
,luent spontaneous refolding can be arrested by the presence of 
t3roEL. GroES is required for enolase to be released from 
t3roEL in the presence of ADP [15]. In a similar manner, 
ecombinant human cpnl0 was capable to effectively release 
~artially folded molecules of yeast enolase from GroEL (Fig. 
*). The above results also clearly indicate that the initial denatu- 
at ion of the recombinant protein and the subsequent RP- 
:IPLC purification did not affect its functionality. 
i 
1 2 3 4 
<-- GroEL  
<-  human cpn lO 
Fig. 3. Silver stained 8 25% SDS-PAGE of GroEL peaks recovered by 
gel filtration. GroEL was pre incubated with recombinant human 
cpnl0 in the presence or absence of ATP (0.6 mM). Lane 1 shows the 
GroEL peak obtained without he addition of ATP; lane 2 shows the 
GroEL peak in the presence of ATE Lane 3 and 4 show pure recombi- 
nant human cpnl0 (Hu-cpnl0) and GroEL, respectively. 
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Fig. 4. Refolding profile of enolase in the presence of GroEL, GroES 
and ADP (open triangles) and in the presence of GroEL, recombinant 
human cpnl0 and ADP (closed squares). The negative control (open 
circles) is performed in the presence of GroEL and ADR The refolding 
was performed at 25°C, as described in section 2. 
4. D iscuss ion 
Several eukaryotic cpn 10 have now been identified and char- 
acterised at the molecular level [6-9,19-20]. Common features 
of these molecules seem to be: (1) lack of any N-terminal prese- 
quence necessary for their targeting to the mitochondrial com- 
partment; (2) removal of the starting methionine, followed by 
N-terminal acetylation of the first amino acid of the mature 
polypeptide; (3) capacity to bind to GroEL, in the presence of 
K + ions and Mg-ATP; and, consequently (4) the ability to 
replace GroES in in vitro assisted refolding experiments, using 
GroEL as cpn60. Conversely, however, GroES was not able to 
replace ukaryotic pnl0 using mammalian cpn60 [21]. 
The first three features have been recently confirmed for pure 
natural human cpnl0 [13]. In addition, the complete primary 
structure of rat cpnl0 has been established [22], indicating 
again modification at the N-terminal amino acid. The authors 
of this report hypothesize that N-terminal acetylation could be 
important for the interaction with cpn60. 
In the present study we have been able to demonstrate hat 
the recombinant form of human cpnl0, lacking N-terminal 
acetylation could still bind to a cpn60 and assist it in the folding 
of a denatured protein. Although it must be stressed that we 
employed an heterologous refolding system using E. coli 
GroEL as cpn60 and yeast enolase as the target for refolding, 
the present results suggest hat N-terminal acetylation is dis- 
pensable for the functionality of eukaryotic pnl0, at least as 
its role in protein refolding is concerned. 
These results extend those published in recent reports ob- 
tained using a C-terminal modified recombinant mouse cpnl0 
[23] and a synthetic rat cpnl0 [24]. In light of recent findings 
suggesting that cpnl0 are multifunctional molecules one may 
also speculate that N-terminal acetylation could be relevant in 
functions other than assisting cpn60 in protein folding. Com- 
parative studies of natural and recombinant cpnl0 in those 
biological systems that have been studied so far only with the 
natural form [13] may help clarify this issue. The availability of 
recombinant human cpnl0 will facilitate to address these stud- 
ies. 
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